FPI-2059 is under clinical development by Fusion Pharmaceuticals and currently in Phase I for Gastric Cancer. According to GlobalData, Phase I drugs for Gastric Cancer have a 77% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how FPI-2059’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
IPN-01087 is under development for recurrent head and neck squamous cell carcinoma, pancreatic, neuroendocrine prostate, colorectal, gastric and Ewing sarcoma.
It is an radioconjugate combining actinium-225 with IPN-1087. It is administered through intravenous route.
It was under development for solid tumors including pancreatic ductal adenocarcinoma, gastric cancer, colorectal cancer, melanoma, head and neck cancer squamous cell carcinoma, Ewing sarcoma and gastrointestinal stromal tumors. The drug candidate is a Neurotensin receptor 1 antagonist. It is developed based on PurAffin technology.
It was also under development for the treatment of small-cell lung cancer.
Fusion Pharmaceuticals overview
Fusion Pharmaceuticals is a clinical-stage biopharmaceutical company which develops targeted alpha-particle radio therapeutics for the treatment of cancers. It offers pipeline products such as FPI-1434, FPI-2059 and FPI-1966. The company’s pipeline products are to treat multiple cancers like head and neck bladder cancer, colorectal cancer and gastric cancers. Fusion Pharmaceuticals carters its products under brand Keytruda. The company is a spin-off from the Centre for Probe Development and Commercialization (CPDC), a leading radiopharmaceutical research and GMP production centre in Canada. It has its operations in the US and Canada. Fusion Pharmaceuticals is headquartered in Hamilton, Ontario, Canada.
For a complete picture of FPI-2059’s drug-specific PTSR and LoA scores, buy the report here.